Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   31/10/2025
64,93 USD (+3,39%)
(+3,39%)   31/10/2025
Grafiek Nektar Therapeutics Grafiek Nektar Therapeutics
donderdag 6 november 2025, 22:15
Kwartaalcijfers (3de kwartaal)

Nektar Therapeutics in het nieuws

30 oktober 2025 · Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London · Persbericht

28 oktober 2025 · Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets · Persbericht

22 oktober 2025 · Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting · Persbericht

18 september 2025 · Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 · Persbericht

9 september 2025 · Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 · Persbericht

4 september 2025 · Nektar Therapeutics to Participate in Two Investor Conferences in September · Persbericht

7 augustus 2025 · Nektar Therapeutics Reports Second Quarter 2025 Financial Results · Persbericht

1 augustus 2025 · Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets · Persbericht

29 juli 2025 · Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata · Persbericht

2 juli 2025 · Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

Profiel Nektar Therapeutics

Biotechnologie
Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Website: www.nektar.com

Hoofdzetel: San Francisco, California vlag Verenigde Staten

Mijn selecties